BG101851A - Hepatitis vaccine - Google Patents

Hepatitis vaccine

Info

Publication number
BG101851A
BG101851A BG101851A BG10185197A BG101851A BG 101851 A BG101851 A BG 101851A BG 101851 A BG101851 A BG 101851A BG 10185197 A BG10185197 A BG 10185197A BG 101851 A BG101851 A BG 101851A
Authority
BG
Bulgaria
Prior art keywords
hepatitis
hepatitis vaccine
vaccine
surfaceantigen
monophosphoryllipid
Prior art date
Application number
BG101851A
Other languages
Bulgarian (bg)
English (en)
Inventor
Pierre Hauser
Nathalie Garcon
Pierre Desmons
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG101851(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of BG101851A publication Critical patent/BG101851A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG101851A 1995-02-25 1997-08-25 Hepatitis vaccine BG101851A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9503863.4A GB9503863D0 (en) 1995-02-25 1995-02-25 Vaccine compositions
PCT/EP1996/000681 WO1996026741A1 (fr) 1995-02-25 1996-02-15 Vaccin a l'hepatite b

Publications (1)

Publication Number Publication Date
BG101851A true BG101851A (en) 1998-04-30

Family

ID=10770292

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101851A BG101851A (en) 1995-02-25 1997-08-25 Hepatitis vaccine

Country Status (36)

Country Link
US (1) US5972346A (fr)
EP (1) EP0810877B1 (fr)
JP (1) JP3881015B2 (fr)
KR (1) KR100365373B1 (fr)
CN (1) CN1101225C (fr)
AP (1) AP766A (fr)
AR (1) AR002279A1 (fr)
AT (1) ATE209045T1 (fr)
AU (1) AU695921B2 (fr)
BG (1) BG101851A (fr)
BR (1) BR9607458A (fr)
CA (1) CA2212552C (fr)
CZ (1) CZ288417B6 (fr)
DE (1) DE69617211T2 (fr)
DK (1) DK0810877T3 (fr)
EA (1) EA199700126A1 (fr)
ES (1) ES2166879T3 (fr)
FI (1) FI118118B (fr)
GB (1) GB9503863D0 (fr)
HK (1) HK1004117A1 (fr)
HU (1) HU224832B1 (fr)
IL (1) IL117249A (fr)
MA (1) MA23814A1 (fr)
MX (1) MX9706450A (fr)
MY (1) MY113428A (fr)
NO (1) NO319394B1 (fr)
NZ (1) NZ302674A (fr)
OA (1) OA10612A (fr)
PL (1) PL182679B1 (fr)
PT (1) PT810877E (fr)
SA (1) SA96160633B1 (fr)
SK (1) SK115097A3 (fr)
TR (1) TR199700849T1 (fr)
TW (1) TW467745B (fr)
WO (1) WO1996026741A1 (fr)
ZA (1) ZA961460B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
CA2347099C (fr) * 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Systemes d'adjuvants comprenant un immunostimulant absorbe sur une particule de sel metallique et vaccins derives
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
WO2000037104A1 (fr) * 1998-12-23 2000-06-29 Merck & Co., Inc. Antigene d'enveloppe d'hepatite b de recombinaison ameliore
IL145982A0 (en) 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
KR20070110513A (ko) * 2005-02-16 2007-11-19 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 알루미늄 포스페이트 및 3ｄ－ｍｐｌ을 포함하는 보조약조성물
NZ565512A (en) * 2005-08-02 2011-08-26 Novartis Vaccines & Diagnostic Reducing interference between oil-containing adjuvants and surfactant-containing antigens
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
CN102727885A (zh) 2005-11-04 2012-10-17 诺华疫苗和诊断有限公司 包含颗粒佐剂和免疫增强剂组合的流感疫苗
WO2007052155A2 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
CA2628152C (fr) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
CN100415294C (zh) * 2005-12-23 2008-09-03 中国农业大学 一种治疗和/或预防乙肝的药物
KR20110110853A (ko) 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
EP2357184B1 (fr) 2006-03-23 2015-02-25 Novartis AG Composés d'imidazoquinoxaline en tant qu'immunomodulateurs
CA2646349A1 (fr) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Stockage de vaccins antigrippaux sans refrigeration
EP1862176A1 (fr) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Procédé de production de composition vaccinale
EP1862177A1 (fr) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Procédé de production de composition vaccinale
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP3456348A1 (fr) 2006-09-11 2019-03-20 Seqirus UK Limited Fabrication de vaccins contre le virus de la grippe sans utiliser d' ufs
CA2671629C (fr) 2006-12-06 2017-08-15 Novartis Ag Vaccins comprenant un antigene issu de quatre souches du virus grippal
CA2692200A1 (fr) 2007-06-27 2008-12-31 Novartis Ag Vaccins antigrippaux a faible teneur en additifs
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081172A1 (fr) 2007-12-24 2009-07-02 Novartis Ag Dosages pour vaccins adsorbés contre la grippe
HUE058971T2 (hu) 2009-07-15 2022-09-28 Glaxosmithkline Biologicals Sa RSV F fehérjekészítmények és eljárások azok elõállítására
PL2667892T3 (pl) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Schemat szczepień przeciwko rsv
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
ES2651143T3 (es) 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SG48175A1 (en) * 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
EP0637223B1 (fr) * 1991-05-29 1998-07-22 Origin Medsystems, Inc. Appareil d'ecartement pour chirurgie endoscopique
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
ATE168271T1 (de) * 1992-05-23 1998-08-15 Smithkline Beecham Biolog Kombinierte impfstoffe, die hepatitis b oberfläche antigen und andere antigenen enthalten
ATE204762T1 (de) * 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9311536D0 (en) * 1993-06-04 1993-07-21 Unilever Plc Hot soluble low density extractable food product

Also Published As

Publication number Publication date
PL321966A1 (en) 1998-01-05
HK1004117A1 (en) 1998-11-20
KR19980702480A (ko) 1998-07-15
KR100365373B1 (ko) 2003-07-07
CA2212552C (fr) 2006-07-11
OA10612A (en) 2002-08-29
HUP9801242A1 (hu) 1998-08-28
MX9706450A (es) 1998-07-31
IL117249A0 (en) 1996-06-18
MA23814A1 (fr) 1996-10-01
BR9607458A (pt) 1998-06-30
PL182679B1 (pl) 2002-02-28
AU4878096A (en) 1996-09-18
JPH11501018A (ja) 1999-01-26
WO1996026741A1 (fr) 1996-09-06
SK115097A3 (en) 1998-02-04
CA2212552A1 (fr) 1996-09-06
DE69617211T2 (de) 2002-07-25
NO319394B1 (no) 2005-08-08
US5972346A (en) 1999-10-26
CZ267497A3 (cs) 1998-02-18
AP766A (en) 1999-09-17
ATE209045T1 (de) 2001-12-15
GB9503863D0 (en) 1995-04-19
CN1176604A (zh) 1998-03-18
CN1101225C (zh) 2003-02-12
SA96160633B1 (ar) 2005-10-15
EP0810877A1 (fr) 1997-12-10
HUP9801242A3 (en) 2000-08-28
NZ302674A (en) 1999-01-28
ZA961460B (en) 1996-08-29
AU695921B2 (en) 1998-08-27
EA199700126A1 (ru) 1998-02-26
NO973873D0 (no) 1997-08-22
AR002279A1 (es) 1998-03-11
EP0810877B1 (fr) 2001-11-21
ES2166879T3 (es) 2002-05-01
NO973873L (no) 1997-08-22
FI973457A (fi) 1997-08-22
TW467745B (en) 2001-12-11
IL117249A (en) 2000-11-21
DE69617211D1 (en) 2002-01-03
AP9701060A0 (en) 1997-10-31
MY113428A (en) 2002-02-28
FI118118B (fi) 2007-07-13
HU224832B1 (en) 2006-03-28
DK0810877T3 (da) 2002-02-25
PT810877E (pt) 2002-04-29
JP3881015B2 (ja) 2007-02-14
TR199700849T1 (xx) 1998-01-21
FI973457A0 (fi) 1997-08-22
CZ288417B6 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
BG101851A (en) Hepatitis vaccine
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
MY111556A (en) Substituted azadioxacycloalkenes.
BG101110A (en) Substituted pyrimidine compounds and their application
DE58906377D1 (en) Difluormethylverbindungen.
EP0621279A3 (fr) Compositions de siloxy-aluminoxane.
AU7636794A (en) Compositions including 1,1,1,2,3,4,4,5,5,5-decafluoropentane
BG101139A (en) Heteroatoms-containing cyclopentanopyridyloxazolidinons
MY121543A (en) Preparation of 3,4,4-trisubstituted-piperidinyl-n- alkylcarboxylates and intermediates
EP0599532A3 (fr) Compositions réticulables monocomposantes d'organosiloxane.
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
AU1397788A (en) Improved shop primer compositions
BG102125A (en) New dolastine derivatives, their preparation and application
MY119388A (en) Microemulsion all purpose liquid cleaning compositions
IN2012DE00109A (fr)
BG103914A (en) Maintained separation of delayed gels
ZA938844B (en) Injectable composition.
BG101892A (en) Sugar-modified cytostatics
AU8974298A (en) 1,4,7,10-tetraazabicyclo{8.2.2}tetradecan-2-one, a process for the preparation thereof and the use thereof for the preparation of tetraazamacrocycles
WO1999017711A3 (fr) Compositions de fixatif capillaire autophobes
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
AU8111282A (en) 1,2,3,6 tetrahydropyridines as anorectic agents
BG101401A (en) Cisaspide extended release oral compositions
EP0656409A3 (fr) Compositions de revêtement.
PL317891A1 (en) Triple composition against hiv